

Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction

Technology Appraisal Guidance No. 52

Issue date October 2002
Review date October 2005

1. Guidance

This guidance provides recommendations on the selection of thrombolytic drugs in patients with acute myocardial infarction (AMI). Recommendations are made in relation to the use of the drugs in hospital and pre-hospital settings. The guidance does not compare hospital and pre-hospital models of delivering thrombolysis.

- 1.1 It is recommended that, in hospital, the choice of thrombolytic drug (alteplase, reteplase, streptokinase or tenecteplase) should take account of:
 - the likely balance of benefit and harm (for example, stroke) to which each of the thrombolytic agents would expose the individual patient
 - current UK clinical practice, in which it is accepted that patients who have previously received streptokinase should not be treated with it again
 - the hospital's arrangements for reducing delays in the administration of thrombolysis.
- 1.2 Where pre-hospital delivery of thrombolytic drugs is considered a beneficial approach as part of an emergency-care pathway for AMI (for example, because of population geography or the accessibility of acute hospital facilities), the practicalities of administering thrombolytic drugs in pre-hospital settings mean that the bolus drugs (reteplase or tenecteplase) are recommended as the preferred option.

This section (Section 1) constitutes the Institute's guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction. The remainder of the document is structured in the following way:

- | | |
|--|---------------------------------|
| 2 Clinical need and practice | 7 Implementation and audit |
| 3 The technology | 8 Related guidance |
| 4 Evidence and interpretation | 9 Review of guidance |
| 5 Recommendations for further research | Appendix A: Appraisal Committee |
| 6 Resource impact for the NHS | Appendix B: Sources of evidence |
| | Appendix C: Patient information |

The full document and a Summary of Evidence are available from our website at www.nice.org.uk or by telephoning 0870 1555 455 and quoting the reference number N0170.

Arweiniad ar ddefnyddio cyffuriau ar gyfer thrombolysis cynnar wrth drin cnawdnychiad myocardaidd aciwt

1. Arweiniad

Mae'r arweiniad hwn yn darparu argymhellion ar y dewis o gyffuriau thrombolytic mewn cleifion â chnawdnychiad myocardaidd aciwt (AMI). Gwneir yr argymhellion mewn perthynas â'r defnydd o'r cyffuriau mewn ysbytai a lleoliadau cyn derbyn claf i'r ysbyty. Nid yw'r arweiniad yn cymharu'r modelau o roi thrombolysis mewn ysbyty a chyn derbyn claf i'r ysbyty.

1.1 Argymhellir y dylid ystyried y canlynol wrth ddewis cyffur thrombolytic mewn ysbyty (alteplase, reteplase, streptokinase neu tenecteplase):

- y cydbwysedd cyffredinol o ran y budd a'r niwed (er enghraift, strôc) y byddai pob claf unigol yn agored iddynt yn sgîl y cyfryngau thrombolytic
- arfer clinigol presennol yn y DU, lle y derbynir na ddylai cleifion sydd wedi derbyn streptokinase o'r blaen gael eu trin ag ef eto
- trefniadau'r ysbyty ar gyfer lleihau oedi wrth roi thrombolysis.

1.2 Pan ystyrir bod y model o roi cyffuriau thrombolytic cyn derbyn claf i'r ysbyty yn ymagwedd fuddiol fel rhan o lwybr gofal brys ar gyfer AMI (er enghraift, oherwydd daearyddiaeth y boblogaeth neu hygyrchedd cyfleusterau ysbyty), gall nodweddion ymarferol y broses o roi cyffuriau thrombolytic mewn lleoliadau cyn derbyn claf i'r ysbyty olygu y caiff cyffuriau bolws (reteplase neu tenecteplase) eu hargymhell fel yr opsiwn gorau.

Arweiniad Arfarnu Technoleg Rhif 52

Dyddiad Cyhoeddi

Hydref 2002

Dyddiad Arolygu

Hydref 2005

Mae'r adran hon (Adran 1) yn ymgorffori arweiniad y Sefydliad ar ddefnyddio cyffuriau ar gyfer thrombolysis cynnar wrth drin cnawdnychiad myocardaidd aciwt. Strwythurir gweddill y ddogfen fel a ganlyn:

- | | |
|--|------------------------------------|
| 2. Angen clinigol ac arfer | 7. Gweithredu ac archwilio |
| 3. Y dechnoleg | 8. Arweiniad cysylltiedig |
| 4. Tystiolaeth a dehongliad | 9. Adolygiad o'r arweiniad |
| 5. Argymhellion ar gyfer ymchwil bellach | Atodiad A: Pwyllgor Arfarnu |
| 6. Effaith adnoddau ar y GIG | Atodiad B: Ffynonellau tystiolaeth |
| | Atodiad C: Gwybodaeth i gleifion |

Mae crynodeb ar gael yn Gymraeg ac yn Saesneg ar ein gwefan yn www.nice.org.uk neu drwy ffonio 0870 1555 455 a dyfynnu cyfeirnod rhif N0170.